SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal[...]

Bicara Therapeutics Inc. published this content on November 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 08, 2025 at 15:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]